Wsorry I am blind and using Siri dictation and apparently she is a little upset asked withAnd if X got a signal that was statistically significant with under 30 people in a study . And they didn't just get a signal in one test play in quite a few different tests. Whereas big Pharma is usually looking for a needle in a haystack of 10,000 people we found multiple needles in a tiny piece of hay. . OK so that incinerates your argument about two smaller study. For an intelligent investor to get excited about and probably a former partner.

As for a lack of placebo be his Storico experience of millions of people who have had the disease well defines the expected course and the FDA has proposed The use of historical placebo in the approval process
Finally it is a special note that the trial was not designed to show statistically significant efficacy and that is why it is so amazing that the so many needles were found in such a small haystack.

The proper term for this is a well conserve molecule which means that it is functioning in an essential roleIf you think it's too simplistic and go .argue with Charles Darwin. It is found in exactly the same form in very primitive and in very modern evolved life. . Apparently it helps to make sure that proteins are put together correctly and connect where they need to connect and that this function evolved very early on and it's essentially unchanged over eons. Maybe on this board are invested in a company that has a similar ability to restore the protein that has been around for 1 billion years that compound works on a protein that when activated make sure that when the DNA is copied it is copied correctly and if it isn't copied correctly that protein causes a process to destroy the sale that has the problems. Evolve very early on in the worms to a sure reproductive accuracy and little modules have been added to it over the years so that it was grabbed in mammalian evolution and used to and sure that not just the reproductive cells but the body cells of the mammals workshop. Th but the bodies own cells were checked for reproductive accuracy. That protein is called the guardian angel of the Gino. So it looks like our protein is the guardian angel of protein synthesis at the mitochondria endoplasm plaza mystic reticulum boundary apologies for being blind and using Siri to write she isn't the brightest crayon in the box sometimes

The fog of war.

We have been burned so many times by AF. Do any of you know if he uses some secret word to indicate that a bash is really a pump, paving the way for another dump??

I son't think so or we would see a spike in the interest rate for borrowing shares.
But , they have taught us well to be paranoid.

Those interest rate posts are very useful.

Question for Rosen lawsuit experts.
Was the claim in the Yahoo article charging the good Dr. For an unrevealed payment for pumping debunked by the court ruling in our favor?

Gigantic wedge formation from Nov 15.

Tech folks, Is there a target for when this wedge breaks on the upside?

The bigger picture.

Not only is sigma 1 ubiquitous and concentrated in every organ with intensive energy needs, but out there in the rest of the world, it is found in almost every animal.
It is also conserved accross many species, ancient and modern in evolutionary terms. That means that the sigma one found in a hotshot crab is almost the same as the one in AFs brain.and where to go and what to do.

What this means that it performs a very essential function, and it's evolution was essential to life.

Having a very long evolutionary. History,it has coevolved with exquisite feedback controls, and enabling regulatory and operational mechanisms.

Unfortunately, for us old farts, evolution does not favor aging. Once. One is past normal reproductive age, ones survival is irrelevant to evolution.
In fact, some theorize that there is evolutionary pressure encouraging aging and death after the age of reproduction and child rearing, as the old were a major. Drag on the tribal resources., or the resources of any other animal population.
That is why my x's guinea pig, Tow Truck, is all stroked out after only a few years.

So it is only natural that such a critical protein malfunctions in old age.
And , there is the miracle. Of systematic ,intelligent science. To discover. The receptor, and to systematically work to find ways to reactivate it.

One thing that I find remarkable is that many on this board are also heavily invested in a company that is in the clinical stage in the study. Of a highly conserved protein that is essential in the fidelity of cellular reproduction, and thus may play. An important part in the control of disease when that molecule. Is re activated.

Both companies are focused on exploiting the the cell's most important regulatory and repair mechanisms that essentially evolved eons ago.

all of the above is based. On my undergraduate level understanding of biology.
Just thought that we sometimes. Forget the really , really big picture.

From my general understanding of biology, I offer the following.

The S1 receptor ,like all receptors, is like a key hole.

Now think of a key hole in an apartment house. there might be a specific. Key that unlocks the front door, and apartment number 42. Another key might might unlock the front door and apartment no 69.

Both keys are unlocking agonists to the front door receptor key hole.
To repeat , they are both general agonists.

But the key that also tickles the Apartment 42 keyhole receptor along with the front door receptor opens up the apartment that contains the reason for life and all existence.
The agonist to the front door and Apartment 69 opens. Up a playground of white fluffy spoons of snow.


Get it,
Got it,
Good.

Investors, including myself, must keep in mind the difference between inevitable and immediate. At some point they converge, but to predict the timing is an unlikely path to success. IMHO

The very large difference between items five and six leaves me to wonder whether there was some error in tabulation.

What if Biogen is testing A273 with its MS compounds. What if they show synergy with one of those already approved compounds. What if Anavex and Biogen partner for a synergic MS play. What if the patent. Office. Gives the combo a patent ? What if the synergic compound also works for other indications. Would that solve the patent issue of 273?that might be better than going it alone with five year protection. Plus some more years for various FDA bonuses.

Not that ther is anything wrong with that.

If the damage is in the wires that transmit information from the memory then if sick wires are repaired and new wires grow the old memories just might come back once they are able to be transmitted by the new wires. I believe that the renewed ability to paint play the piano golf etc. indicates this possibility and possibly some of the more objective tests that were measured in the study

Herr Hair said that the sigma one receptor was like a fire truck. It only shows up when there is a fire..

to keep his analogy, . If you have a fire truck that has a dead battery, A273 gives the sigma fire truck a hot shot, and off it goes to fight the fire.

But you were talking about a single neuron. So I will tweak the analogy. the house is on fire. The sprinklers are stuck off. A273 is like a swarm of tiny drones that fly into the burning house and turn on the sigma sprinklers, putting out the fire in the Neuron house. Of course, if the wife had not been baking pizza, and playing with the prophylactics, none of this would be necessary.??

Of course the sigma one receptor is well conserved so it is actually unlikely to very much There are many things that can affect how well the drug works. These could include absorption due to differences in bacteria or health, genetic differences in absorption, various abilities of the liver to metabolize the drug, variations in the degree of damage in the brain that cannot be fixed variations in the genetics of the singer one receptor the list is endless

The FDA's' adaptive trial design is a major break from the traditional placebo control.

At it's core, it relies on the ability to have many different tests for indicating disease and the lack of it.
In each of those measured disease aspects, one can look for a dose response.
The Pk data will give a more accurate measurement of the actual dose that reaches the bloodstream of each patient, and be compared to the measured outcome of disease.
An upward sloping dose response curve for the group. In each disease category would add strength to the power of the analysis.

He has the PK data as the first reveal in the list, so it is coming soon, probably at the conference coming up.

It's gonna be really great. It is gonna be Huuuugh. And soon.
Now wether the market will get it, that is another story.
And the entrenched thinking at Big Pharma is another story.
I think this will shake them loose.

Wow, don't know if I will sleep well tonight, or just howl at the moon with my Pit.

Could the manipulators today be the long axon hedges trying to keep their scam alive as it sinks. Axon was down $.55 last time I looked

The important metric for any reasonable long-term investor who is concerned about value per share, Space is the number of shares outstanding Plus The number of warrants and Options. I would request one of the more diligent people on this board to compare shares fully diluted during those two time periods and I believe you will see that the change was not particularly significant many of the shares that were added to the float over the last year and a half were from exercised warrants and Options and exercise did not affect the shares outstanding fully diluted number which is the important number

I wish I knew what the price would be. A wild ass guess would be somewhere between five and 10 billion in a combination of stock and cash

The partnership also may be geographically limited to the United States

That is when AF opened his mouth and ordered the shortcut bow to start the printing presses on fraudulent shares
They're fixed it for you.

Trying to figure what is going on in Washington, I have gotten in the habit of always thinking that the logic of the public action is often the opposite of the real hidden agenda.

I have stated before that Biogen desperately needs AVXL, and just might be happy ponying up to the Hairy Doctor's demands.

But the Biogen management has two problems. It can't afford to look like it overspent to it's shareholders, and possibly the Board. It also needs a high valuation for the AVXL assets that it acquires,in order to keep it's bankers and rating agencies happy.

So maybe the poisin pill is there to attract interest from the market. Maybe it is there to entice potential to the bargaining table in a public way. Either of those actions would potentially spike the valuation of AVXL to the point which would be good for us, and not too embarrassing for the Biogen management.

Capiche.

How long have they been working with the FDA on the next phase of the ALZ trials? The FDA wheels grind slowly, but once The FDA. And ANVX have worked out all the kinks, and decided on meaningful objectives, the trials can go forward, with assurance. That the goal posts will not be moved by the FDA. Of course, assurances. Are not guarantees.From what Dr. McFarlan has said, what the Australian .gov has paid, and from the fact that the in Vivian chemistry. Has been worked out, plus the general demeanor of Herr Hair, methinks we get the green light by end of June. Similar arguements apply. For RETS and Parkinson's.

We have discussed before the probability that most of the volume up. And down in the spike to 14 was wash trades by AF and his merry band of. Racketeers.

Thats why it is probable that there are not many underwater owners of AVXL at this time IMHO.

There is an interesting article on ZeroHedge.com tonight entitled The most unloved bubble ever.
The author points out one big thing about this bubble. Nobody is bragging at cocktail parties. There are no shoeshine boys speculating. In fact , everybody is complaining about the insane valuations. Everybody has moved away from risk to big caps ,bonds, utilities etc.

This little biotech has already had all the spec squeezed out of it. There are probably only extremely informed and steadfast retail left. This article added more solid zzzzzzzs to my sleep, because if the market sells off, it is the perceived less risky stocks that will plunge. We have already done our plunging and vaporization of weak longs.

IMHO

Most humorous post ever. EOM

I'm sorry if I have to say it again but the management of bio Jen needs us as much as we need them but they are going to have to pay to come to an agreement with the good doctor and the shareholders of bio Jen as well as the board of bio Jen will revolt if the management of bio Jen pays to high of a multiple and either a buyout or a partnership agreement therefore I think it is reasonable to assume that bio Jen management would like to see a higher price not a lower one at this point

IMHO, there are no effective drugs for depression, although some might be able to pass a test for some marginal improvements on some statistically significant portion. Of the tested population.

from my personal experience , and reading of the published evidence, properly taught, and practiced,and practiced and practiced CEBT, Cognitive Emotive Behavior Therapy, can and does work. For those who work at understanding it and practice, practice, practice.

The Youtubes of Albert Ellis are a terrific start, as. Are his books on Amazon, The best for me is How to refuse to make yourself miserable about anything, yes anything".

BTW, the insights were a big help November. A year ago and last august, sigh.

Please excuse the typos,esp YouTube , as I am blind and still learning how to edit.

I am hopeful that anavex will help stabilize and probably improve my vision, as it is an autoimmune deterioration of. The retina, the optic nerve, and the supporting cells.

I also think it will help the neuropathy in my legs brought on by the same autoimmune reaction to residual antigens from prior opportunistic infections when I had full blown AIDS.

But the $$$$ might have an even stronger curative effect??

Many. Of the the large retail holders of this stock bought on the advice of Patrick Cox many years ago, or had attention directed to CTIX. Another recommendation of Mr. Cox's has been active. Over the last few months. There may be some transfer of interest between the two at this time, which may be causing weakness, but may in turn cause strength later.

Lots of chatter here that show why we don't need a patent. There are many paths to exclusivity, and they are provided in law as recognition that the FDA process can eat up an entire patent before approval, or much of it. Big pharma are masters of working the various exclusions for quite a while. This is not ruling out that we might get a combo approval.

One of the advantages of a potential. AVXL Biogen, that Biogen could do a combo trial with one of it's MS drugs, or maybe even one of it's ALZ candidates, and get a brand spanking new patent for the combo.
But there are plenty of paths to at least nine years exclusivity, and probably much more under existing law. There are many previous posts that detail and link to. The history and regulations.

There is a lot of retail myself included who are way overweight the stock it is only human nature for others to take advantage of the natural psychology of that position. The same thing has repeatedly happened with my largest position bit coin which has gone from 30 to 1100 during my tenure so relax this will be over in a few days or weeks or months. Meanwhile the neurons are doing what they're doing in bio Jen's test tubes and in the brains of our wonderful folks in Australia. The wheels of the FTA are grinding slowly but surely towards the start of our three trials. And then the neurons in our little girls in our poor shaking Parkinson's folks in and the folks in Australia will do their work

Most of us are pretty sure this is a dead end but I thought I'd post it anyway

https://medicine.wustl.edu/news/drug-compound-halts-alzheimers-related-damage-mice/?utm_source=%40Washington&utm_medium=email&utm_content=Alzheimer's%20disease%20treatment%20tau%20protein%20Timothy%20Miller%20antisense%20oligonucleotides

Biogen has to do two things to buy at AV XL out first of all he has to meet our price and second of all the management does not want to look like they overpaid. So a bio Jen announcement of the results could indicate that bio Jen needs a higher market price in order to not be embarrassed when they meet the price that the good Dr. Deands.

The friends that were in it got bored and sold. Mums The word now

Huh. Two thousand cases at 250k a pop is five hundred million in revenue., just in US, this should give a five billion market cap, thats over one hundred a share at a PE of 10, not to. that kind of price tag is not unusual for a pediatric orphan drug.

Of course, at that price, there will probably be a few thousand billionaires taking it off label.

TOf course , the price will decline a lot for the more common diseases.
so thirty bucks is pretty good bet for RETS.

Either way the transaction would've had to cross the tape

That headpiece was so weak it almost seems like a pump. Just something to keep in the back of their heads. We need to keep an eye on the broker loan rate and if that goes way up along with a more credible hit piece then they are back

The best interest of the shareholders is to do everything possible to prevent an early hostile takeover. Poison pills might work. However, partnerships are a terrific poisin pill, as they can contain very toxic clauses for the hostile acquirer.. In a world where the big banks live on Mand A, and have written the rules to keep them flowing, a voluntary partnership with a big enough beast that cannot also be swallowed by the wolves, is thus very much in the cards. Nobody knows biology and Wall Street bankster ways better than the good doctor. That is why a partnership is sooner than later. IMHO

I have a few questions that I really should know by now.
what percentage is Biogen allowed to buy before they must PR.
How much time do they have to do the PR after they stop buying.

Can AVXL just make a deal where they sell fifty percent of the company to Biogen for x billion? Would they need shareholder approval?
Or maybe AVXL form a joint venture?

The ideal would be a nice chunk of change now for the shareholders and a big piece. Of the future. And as I posted before, IMHO Biogen can't buy this too cheap, becauseHerr Hair wont do it. So the market price needs to get to the Drs price. With the market showing a nice high price, then Biogen can get in bed with Anavex for a tidy sum, and the Biogen stockholders wont be too upset about the price.

Plus, AVXL needs to have more recognition so that it's halo shines on Biogen when the deal is done.

this is just how all the pieces look to me.
Would appreciate more input for those who know the rules of all this M and A, and partnership stuff. In other words , I think that the DR. And Biogen have given so many hints in PR phrasing and body language in public, that they are working in concert. IIMHO Biogen needs us bad, and is anxious to get the market price of AVXL up so when they write the check, the shareholders don't look so bad.

The most damaging news counter to this is the fact that Biogen has ratings issues with the banksters. So we might just be getting some freshly printed biogen shares.

One has to remember that the animal results over multiple conditions were unprecedented. Soon we will have human results in multiple conditionsbased on a solid theory of the method of action.

Exactly. does any adaptation have to be published at .gov or 10k? I do not think so, but am open to better informed posters information.

Can you show me any responders in any previous study by any company or institution that improved in such a large set of measurements to the extent at the top responders improved in the Australia study?